Clinical data | |
---|---|
Trade names | Hidrasec, Tiorfan |
AHFS/Drugs.com | International Drug Names |
Routes of administration |
Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 90% (active thiorphan metabolite) |
Metabolism | Liver-mediated |
Biological half-life | 3 hours |
Excretion | Urine (81.4%), feces (8%) |
Identifiers | |
|
|
Synonyms | Benzyl 2-[3-(acetylthio)-2-benzylpropanamido]acetate |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
ECHA InfoCard | 100.214.352 |
Chemical and physical data | |
Formula | C21H23NO4S |
Molar mass | 385.47662 g/mol |
3D model (Jmol) | |
Chirality | Racemic mixture |
|
|
|
|
(what is this?) |
Racecadotril, also known as acetorphan, is an antidiarrheal drug which acts as a peripherally acting enkephalinase inhibitor. Unlike other opioid medications used to treat diarrhea, which reduce intestinal motility, racecadotril has an effect—it reduces the secretion of water and electrolytes into the intestine. It is available in France (where it was first introduced in ~1990) and other European countries (including Germany, Italy, the UK, Spain and the Czech Republic) as well as most of South America and some South East Asian countries (including China, India and Thailand), but not in the United States. It is sold under the tradenames Hidrasec or, in France, Tiorfan. In Italy it is sold under the tradename Tiorfix.
Thiorphan is the active metabolite of racecadotril, which exerts the bulk of its inhibitory actions on enkephalinase.